Product Information
MYRBETRIQ ER 25 MG TABLET is a brand product labeled by Astellas Pharma US, Inc., priced at $14.6784 per EA under NDC 00469260190. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Jun 28, 2012. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
25 mg/1
Manufacturer
Astellas Pharma US, Inc.NDC
00469260190
Classification
Brand
Dosage Form
TABLET, FILM COATED, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
MIRABEGRONApproval Type
New Drug (NDA)
FDA Application
NDA202611FDA Approved
6/28/2012
TE Code
AB
On Market Since
6/28/2012
Pharmacological Classes
Price Statistics
The NADAC for MYRBETRIQ ER 25 MG TABLET has been published 671 times since Nov 28, 2013, and over the history we have for it it has risen 100.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $14.6784 per EA |
|---|---|
| All-time high | $14.7215 (Sep 11, 2024) |
| All-time low | $7.3260 (Nov 28, 2013) |
| 52-week high | $14.6991 |
| 52-week low | $14.6784 |
| Median price | $12.9517 |
| Average price | $12.0739 |
| Largest weekly change | +9.9% (Feb 25, 2015) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 37% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Astellas Pharma US, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
mirabegron market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
beta3-Adrenergic Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of MYRBETRIQ ER 25 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for MYRBETRIQ ER 25 MG TABLET, manufactured by Astellas Pharma US, Inc., is $14.6784 per EA (NDC 00469260190), effective Sep 30, 2026.
How has the price of MYRBETRIQ ER 25 MG TABLET changed over time?
Over the history we have for it, the NADAC for MYRBETRIQ ER 25 MG TABLET has risen 100.4%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for MYRBETRIQ ER 25 MG TABLET?
Since Nov 28, 2013, the NADAC for MYRBETRIQ ER 25 MG TABLET has ranged from a low of $7.3260 (Nov 28, 2013) to a high of $14.7215 (Sep 11, 2024), with a median of $12.9517 per EA.
Are there cheaper alternatives to MYRBETRIQ ER 25 MG TABLET?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, MIRABEGRON ER 25 MG TABLET, is $9.1767 per EA — about 37% below MYRBETRIQ ER 25 MG TABLET.
Who manufactures MYRBETRIQ ER 25 MG TABLET?
MYRBETRIQ ER 25 MG TABLET (NDC 00469260190) is labeled by Astellas Pharma US, Inc., and CMS classifies it as a brand product.